Development of a new minimally invasive and continuously measurable biomarker in colorectal cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K20809
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0901:Oncology and related fields
• Research Institution: Wakayama Medical University
• Principal Investigator: NAKAMURA Yuki 和歌山県立医科大学, 医学部, 助教 (30909528)
• Project Period (FY): 2021-08-30 – 2023-03-31
• Keywords: リキッドバイオプシー / circulating tumor DNA / 大腸癌

Outline of Final Research Achievements

Blood and urine samples were collected in the perioperative period of colorectal cancer. Cell free DNA (cfDNA) in blood and urine was extracted, and KRAS mutated ctDNA was measured by digital droplet PCR.
In 78 patients who underwent colorectal cancer surgery at our department, the preoperative detection rate of KRAS mutated ctDNA was 20.0% in blood and 12.8% in urine, which was higher in blood, but when measured over time after surgery, the detection rate was higher in urine after the day of surgery.In addition, the changes in urinary ctDNA over time during the perioperative period could be classified into several categories.

Free Research Field

大腸癌

Academic Significance and Societal Importance of the Research Achievements

本研究において、大腸癌周術期に血中および尿中のKRAS変異ctDNAの測定を行い、尿中においてもctDNAの経時的な変化を捉えることが出来た。尿中ctDNAの測定は非常に低侵襲に可能であり、経時的な測定に適していると考えられる。本研究におけるこれまでの結果から、尿中ctDNAは大腸癌周術期において鋭敏に測定可能であることから、バイオマーカーとして有用となりうる可能性が示唆された。